氟达拉宾、米托蒽醌、地塞米松治疗难治性低度恶性淋巴瘤的临床观察

Clinical observation of fludarabine\mitoxantrone\dexamethasone in refractory low-degree malignant lymphoma

目的观察氟达拉宾、米托蒽醌、地塞米松(FMD方案)治疗难治性低度恶性淋巴瘤的疗效和不良反应。方法15例Ⅲ-Ⅳ期难治性低度恶性淋巴瘤患者接受FMD方案联合化疗。结果15例患者中10例有效(66.7%),5例完全缓解(33.3%),5例部分缓解(33.3%),3例稳定(20%),2例进展(13.3%)。不良反应轻微。结论FMD方案对难治性低度恶性淋巴瘤疗效肯定,安全,值得临床推广运用。

[Objective] To observe the efficacy and safety of fludarabine／mitoxantrone／dexamethasone （FMD regiment） in refractory low-degree malignant lymphoma. [Methods] Fifteen patients with refractory low-degree malignant lymphoma were administered with FMD regiment. [Results] Among fifteen patients, ten had response and the overall response rate was 66.7%, five patients were complete remission （33.3%）, five patients were partial remission （33.3%）, three patients were stable （20%）, and two patients were aggravated （13.3%）. All patients had mild adverse effect. [Conclusion] FMD regiment has satisfactory efficacy in the treatment of refractory low-degree malignant lymphoma with mild adverse effect.